Dermira’s (NASDAQ:DERM) Phase 2b dose-ranging study of lebrikizumab in atopic dermatitis demonstrated that all three doses achieved greater improvements in the Eczema Area and Severity Index score, compared with placebo.
Lebrikizumab is a humanized monoclonal antibody that targets interleukin-13, which promotes inflammation and is believed to play a major role in the pathophysiology of atopic dermatitis.
Demria plans to hold an end-of-Phase 2 meeting with the FDA and initiate a Phase 3 clinical development program by the end of 2019.
